1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The MCAS cell line was derived from mucinous cystadenocarcinoma of the ovary and has a doubling time of 27 hours, according to the original published paper. In culture, these cells form a monolayer with a pavement-like cellular arrangement. They exhibit rather large cells with vacuoles in the cytoplasm when confluent, and PAS staining shows positivity specifically in these large cells. Chromosomal analysis indicates a peritetraploid tendency. When heterotransplanted into nude athymic mice, MCAS cells develop tumors with both cystic and solid components, making them a valuable tool for ovarian cancer research.
Why choose MCAS from AcceGen?
The MCAS cell line from AcceGen offers superior quality and viability, maintained under sterile conditions, and certified negative for bacteria, fungi, and mycoplasma. To ensure safety, PCR assays confirm the absence of human pathogens. Identity is verified through STR analysis, making it a reliable resource for research applications.
| Species | Human |
| Cat.No | ABL-TC0396 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The MCAS cell line is a crucial asset in the field of human ovarian carcinoma research, particularly for investigating potential treatments and underlying mechanisms for inhibiting the growth of mucinous ovarian carcinoma tumor cells. Researchers employ MCAS cells to identify drugs and study their effects, shedding light on promising molecular therapies. This cell line serves as a valuable tool to explore novel therapeutic strategies and develop a deeper understanding of mucinous ovarian carcinoma, ultimately contributing to advancements in cancer treatment.
